| human | Q5 |
| P496 | ORCID iD | 0000-0002-3147-8037 |
| P1153 | Scopus author ID | 7007013574 |
| P734 | family name | Press | Q16881394 |
| Press | Q16881394 | ||
| Press | Q16881394 | ||
| P735 | given name | Oliver | Q2110096 |
| Oliver | Q2110096 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q35849468 | 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. |
| Q36987727 | 131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes |
| Q34216815 | 90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistribution |
| Q27684407 | A Computationally Designed Inhibitor of an Epstein-Barr Viral Bcl-2 Protein Induces Apoptosis in Infected Cells |
| Q37412360 | A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. |
| Q74595839 | A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts |
| Q40296288 | A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. |
| Q37708518 | A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. |
| Q44435109 | A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911 |
| Q30538453 | A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma. |
| Q73119226 | A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas |
| Q37675882 | A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. |
| Q39627657 | A pretargeted nanoparticle system for tumor cell labeling |
| Q83190874 | A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation |
| Q36973229 | A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT |
| Q37169112 | A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. |
| Q42688168 | A roadmap for discovery and translation in lymphoma. |
| Q68812518 | A simplified microassay for inhibition of protein synthesis in reticulocyte lysates by immunotoxins |
| Q43992785 | A streptavidin-biotin binding system that minimizes blocking by endogenous biotin. |
| Q36630075 | A technology platform to assess multiple cancer agents simultaneously within a patient's tumor |
| Q46433183 | Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older |
| Q36868712 | Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells |
| Q71079831 | Advances in immunotoxin biology and therapy: a summary of the Fourth International Symposium on Immunotoxins |
| Q37697843 | Advances in the treatment of hematologic malignancies using immunoconjugates |
| Q33560410 | Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome |
| Q72621743 | Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience |
| Q38719863 | Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications |
| Q48222343 | Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. |
| Q24629826 | Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model |
| Q34612119 | Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model |
| Q36488985 | Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment |
| Q33560416 | Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice |
| Q36979111 | Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. |
| Q74213454 | Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies |
| Q36054254 | Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. |
| Q35220659 | Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. |
| Q74604560 | Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens |
| Q37313790 | Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma |
| Q81383380 | Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model |
| Q37133715 | Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211 |
| Q38847015 | Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation. |
| Q35196478 | Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status |
| Q47329597 | CD38 bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B cell malignancies. |
| Q54338603 | Characterization of HER2 status by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). |
| Q36826893 | Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015 |
| Q33773139 | Clinical applications of anti-CD20 antibodies. |
| Q89777688 | Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL |
| Q28537688 | Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma |
| Q41914086 | Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma |
| Q38799356 | Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers |
| Q27311386 | Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models |
| Q71046862 | Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells |
| Q44225929 | Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. |
| Q44350601 | Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. |
| Q81307982 | Comparison of radiation dose estimation for myeloablative radioimmunotherapy for relapsed or recurrent mantle cell lymphoma using (131)I tositumomab to that of other types of non-Hodgkin's lymphoma |
| Q40634356 | Conditionally cleavable radioimmunoconjugates: a novel approach for the release of radioisotopes from radioimmunoconjugates. |
| Q72169087 | Constitutive endocytosis and degradation of CD22 by human B cells |
| Q34360360 | Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. |
| Q37398969 | Cutaneous T-cell lymphoma in sub-Saharan Africa |
| Q41452911 | Degradation of ricin A chain by endosomal and lysosomal enzymes--the protective role of ricin B chain |
| Q34029619 | Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants. |
| Q72529067 | Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation |
| Q40674010 | Differences in lifespan and rate of turnover between phytohaemagglutinin responsive cells of the bone marrow and of peripheral lymphoid organs |
| Q87238648 | Diffuse Large B-Cell Lymphoma Version 1.2016 |
| Q46568139 | Drs Ramsey and Press Reply. |
| Q70064475 | Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease |
| Q34477705 | Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium |
| Q43586521 | Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. |
| Q35056309 | Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. |
| Q73849063 | Emerging immunotherapies for non-Hodgkin lymphomas: the tortoise approaches the finish line |
| Q69522036 | Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies |
| Q70049301 | Endocytosis and degradation of murine anti-human CD3 monoclonal antibodies by normal and malignant T-lymphocytes |
| Q48145247 | Enzyme-Cleavable Polymeric Micelles for the Intracellular Delivery of Proapoptotic Peptides. |
| Q34637897 | Epidemiology, Diagnosis, and Treatment of HIV-Associated Non-Hodgkin Lymphoma in Resource-Limited Settings. |
| Q36445890 | Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. |
| Q50636177 | Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies |
| Q52982144 | FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. |
| Q37458703 | Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. |
| Q40604062 | Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. |
| Q77435841 | Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue |
| Q41860499 | Gemcitabine and Chlorotoxin Conjugated Iron Oxide Nanoparticles for Glioblastoma Therapy |
| Q34137865 | Gender-related survival differences associated with polymorphic variants of estrogen receptor-β (ERβ) in patients with metastatic colon cancer. |
| Q93182953 | Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016 |
| Q41693335 | Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. |
| Q46528882 | Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133. |
| Q77807289 | Hemolytic activity of pH-responsive polymer-streptavidin bioconjugates |
| Q71299408 | High dose radioimmunotherapy in malignant lymphoma |
| Q68697755 | High dose radiolabeled antibody therapy of lymphoma |
| Q47386286 | High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes. |
| Q36469671 | High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma |
| Q53570081 | High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. |
| Q74122732 | High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease |
| Q43966195 | High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma |
| Q46298914 | High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. |
| Q72790348 | High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy |
| Q71592626 | High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells |
| Q68511084 | High-dose radioimmunotherapy of B cell lymphomas |
| Q44443172 | High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. |
| Q35223780 | Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation |
| Q41614459 | IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer |
| Q34876695 | Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313 |
| Q54431436 | Imaging and treatment of B-cell lymphoma. |
| Q34448626 | Immunotherapy of Non-Hodgkin's lymphomas. |
| Q70127097 | Immunotoxins |
| Q53024902 | Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. |
| Q37347239 | Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma |
| Q73834761 | Importance of pre-treatment radiation absorbed dose estimation for radioimmunotherapy of non-Hodgkin's lymphoma |
| Q36306177 | Improved conditioning regimens for autologous transplantation using targeted radiotherapy |
| Q45807575 | Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies? |
| Q36511565 | Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy |
| Q37720291 | In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs |
| Q34353363 | In vivo localization of ⁹⁰Y and ¹⁷⁷Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model |
| Q73254080 | Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation |
| Q40401154 | Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas. |
| Q41944363 | Inhibition of catabolism of radiolabeled antibodies by tumor cells using lysosomotropic amines and carboxylic ionophores. |
| Q73115420 | Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study |
| Q41662811 | Intracellular catabolism of radiolabeled anti-CD3 antibodies by leukemic T cells |
| Q41624099 | Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells. |
| Q35594851 | Intracellular delivery system for antibody-Peptide drug conjugates |
| Q35813561 | Is there a better way to deliver total body irradiation? |
| Q41647059 | Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model |
| Q42155557 | Localized beta dosimetry of 131 I ‐labeled antibodies in follicular lymphoma |
| Q93219203 | Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma |
| Q33419003 | Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation |
| Q35501693 | Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies |
| Q46318833 | Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. |
| Q30670674 | Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma |
| Q44953022 | Mantle cell lymphoma: report of the 2009 Mantle Cell Lymphoma Consortium Workshop |
| Q30452448 | Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop |
| Q33960119 | Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation |
| Q38504989 | Mechanisms and clinical applications of chromosomal instability in lymphoid malignancy |
| Q50217130 | Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas. |
| Q74372881 | Modification of ricin A chain, by addition of endoplasmic reticulum (KDEL) or Golgi (YQRL) retention sequences, enhances its cytotoxicity and translocation |
| Q68812167 | Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas |
| Q81087251 | Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose |
| Q33605275 | Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma |
| Q40424134 | Myeloablative Radiolabeled Antibody Therapy with Autologous Bone marrow Transplantation for Relapsed B Cell Lymphomas |
| Q34102089 | NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas |
| Q43753478 | NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017. |
| Q47607400 | NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. |
| Q77606769 | Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies |
| Q73209267 | Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells |
| Q73303821 | Non-FcR-binding, humanized anti-CD3 antibody Hu291 induces apoptosis of human T cells more effectively than OKT3 and is immunosuppressive in vivo |
| Q85636631 | Non-Hodgkin's Lymphomas, version 3.2012 |
| Q82684094 | Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology |
| Q81144359 | Non-Hodgkin's lymphomas |
| Q84061371 | Non-Hodgkin's lymphomas |
| Q45276579 | Non-Hodgkin's lymphomas, version 1.2013. |
| Q88071273 | Non-Hodgkin's lymphomas, version 2.2014 |
| Q36820885 | Non-Hodgkin's lymphomas, version 4.2014. |
| Q33433426 | Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial |
| Q80765390 | Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains |
| Q71758446 | Pancytopenia in mannosidosis |
| Q50223662 | Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy |
| Q78102284 | Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome |
| Q44656909 | Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. |
| Q53251676 | Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. |
| Q34646321 | Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. |
| Q36335858 | Phytohemagglutinin-induced differentiation and blastogenesis of precursor T cells from mouse bone marrow |
| Q34386601 | Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. |
| Q72826625 | Post therapy imaging in high dose I-131 radioimmunotherapy patients |
| Q47564275 | Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions. |
| Q30764873 | Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. |
| Q34113941 | Pretargeted radioimmunotherapy for hematologic and other malignancies |
| Q37036289 | Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia. |
| Q35589582 | Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma |
| Q50665504 | Pretargeting with bispecific fusion proteins facilitates delivery of nanoparticles to tumor cells with distinct surface antigens |
| Q34166809 | Principles of radioimmunotherapy for hematologists and oncologists. |
| Q33873518 | Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study. |
| Q47807412 | Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates. |
| Q71730954 | Pseudotumor cerebri and hypothyroidism |
| Q67540547 | Qualitative differences in the lymphocyte phytohemagglutinin (PHA) response between the bone marrow and other lymphoid organs |
| Q35726245 | Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera |
| Q33934326 | R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. |
| Q40150317 | Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma. |
| Q33424056 | Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission |
| Q53389200 | Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective. |
| Q28088825 | Radioimmunotherapy of human tumours |
| Q34022682 | Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome |
| Q42820682 | Radiolabeled antibody targeting of the HER-2/neu oncoprotein |
| Q67879374 | Radiolabeled antibody therapy of human B cell lymphomas |
| Q40711919 | Radiolabeled antibody therapy of lymphoma. |
| Q40481452 | Radiolabeled antibody therapy of lymphomas. |
| Q44080136 | Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support |
| Q37380415 | Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study |
| Q89949611 | Reply to H.J.A. Adams et al and E.A. Hawkes et al |
| Q55284071 | Reply to “Fc gamma receptor 3a genotype in follicular lymphoma: the end of the story?” Haematologica. 2012;97(11):e45. |
| Q50211518 | Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma |
| Q72267468 | Retention of B-cell-specific monoclonal antibodies by human lymphoma cells |
| Q43437207 | Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells. |
| Q37033240 | Risk of non-Hodgkin lymphoma in relation to tricyclic antidepressant use. |
| Q36787584 | Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. |
| Q45228619 | Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma. |
| Q41272702 | Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. |
| Q86491334 | Selection of first-line therapy for advanced follicular lymphoma |
| Q39609256 | Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. |
| Q73638542 | Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells |
| Q84101645 | Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission |
| Q35575328 | Stable and efficient Paclitaxel nanoparticles for targeted glioblastoma therapy |
| Q43992791 | Streptavidin in antibody pretargeting. 3. Comparison of biotin binding and tissue localization of 1,2-cyclohexanedione and succinic anhydride modified recombinant streptavidin. |
| Q43698946 | Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells. |
| Q42549120 | T-cell immunotherapy: looking forward |
| Q80400532 | Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate |
| Q73884631 | Targeted therapy for hematologic malignancies: has its promise been realized? |
| Q38902260 | Temozolomide nanoparticles for targeted glioblastoma therapy |
| Q40705833 | The differentiation of B and T lymphocytes from precursor cells resident in the bone marrow |
| Q40657177 | The distribution of rapidly and slowly renewed T, B, and “null” lymphocytes in mouse bone marrow, thymus, lymph nodes, and spleen |
| Q46961773 | The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma. |
| Q41615778 | The potential for immunoconjugates in lymphoma therapy. |
| Q51904511 | The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation. |
| Q40679339 | The relative importance of the bone marrow and spleen in the production and dissemination of B lymphocytes |
| Q34679582 | The use of radioimmunoconjugates in stem cell transplantation. |
| Q67585402 | The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia |
| Q41385468 | The use of radiolabeled antibodies in bone marrow transplantation for hematologic malignancies. |
| Q33931377 | Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience. |
| Q47736116 | Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma |
| Q41283888 | Translocation of ricin A-chain into proteoliposomes reconstituted from Golgi and endoplasmic reticulum. |
| Q37419728 | Treatment of lymphoma with adoptively transferred T cells. |
| Q69520763 | Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody |
| Q68207061 | Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation |
| Q37138259 | US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. |
| Q50200754 | Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas |
| Q35751371 | Well-defined single polymer nanoparticles for the antibody-targeted delivery of chemotherapeutic agents. |
| Q50203410 | Whither Radioimmunotherapy: To Be or Not To Be? |
| Q90466721 | Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia |
| Q58602126 | cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies |
| Q36362587 | α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation |
| Q36905562 | ⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma |
| Oliver Press | wikipedia |
Search more.